Concepts (148)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Neoplasms | 8 | 2009 | 124 | 1.300 |
Why?
|
| Arnold-Chiari Malformation | 5 | 2015 | 11 | 1.200 |
Why?
|
| Cancer Vaccines | 4 | 2012 | 10 | 1.090 |
Why?
|
| Fibroblasts | 6 | 2008 | 95 | 0.950 |
Why?
|
| Cerebrospinal Fluid | 5 | 2005 | 18 | 0.900 |
Why?
|
| Interleukin-2 | 6 | 2008 | 66 | 0.810 |
Why?
|
| Glioma | 6 | 2009 | 47 | 0.640 |
Why?
|
| Intracranial Pressure | 3 | 2006 | 21 | 0.560 |
Why?
|
| Neoplasms | 3 | 2015 | 247 | 0.560 |
Why?
|
| Antineoplastic Agents | 4 | 2007 | 218 | 0.540 |
Why?
|
| Syringomyelia | 2 | 2005 | 12 | 0.540 |
Why?
|
| Arachnoid Cysts | 2 | 2005 | 6 | 0.530 |
Why?
|
| Cerebrospinal Fluid Pressure | 2 | 2005 | 4 | 0.530 |
Why?
|
| Cerebrovascular Circulation | 2 | 2005 | 43 | 0.490 |
Why?
|
| Vaccines, DNA | 1 | 2012 | 6 | 0.430 |
Why?
|
| Antigens, Neoplasm | 1 | 2012 | 37 | 0.420 |
Why?
|
| Magnetic Resonance Imaging | 7 | 2015 | 1221 | 0.410 |
Why?
|
| Compliance | 3 | 2005 | 6 | 0.390 |
Why?
|
| Mice | 11 | 2012 | 1607 | 0.390 |
Why?
|
| PPAR gamma | 2 | 2007 | 12 | 0.380 |
Why?
|
| Thiazolidinediones | 2 | 2007 | 14 | 0.380 |
Why?
|
| Decompression, Surgical | 3 | 2005 | 141 | 0.340 |
Why?
|
| Mice, Inbred C3H | 5 | 2012 | 33 | 0.330 |
Why?
|
| Breast Neoplasms | 3 | 2008 | 329 | 0.300 |
Why?
|
| T-Lymphocytes, Regulatory | 4 | 2015 | 49 | 0.300 |
Why?
|
| Animals | 11 | 2012 | 4552 | 0.290 |
Why?
|
| Amyloid beta-Peptides | 2 | 2004 | 294 | 0.270 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2005 | 2 | 0.270 |
Why?
|
| DNA, Neoplasm | 1 | 2005 | 25 | 0.270 |
Why?
|
| Interleukins | 1 | 2005 | 37 | 0.270 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2004 | 8 | 0.260 |
Why?
|
| Third Ventricle | 1 | 2004 | 4 | 0.260 |
Why?
|
| Plaque, Amyloid | 1 | 2004 | 144 | 0.240 |
Why?
|
| Microglia | 1 | 2004 | 124 | 0.240 |
Why?
|
| Mice, Inbred C57BL | 7 | 2007 | 432 | 0.240 |
Why?
|
| T-Lymphocytes | 3 | 2012 | 211 | 0.230 |
Why?
|
| Cell Line, Tumor | 4 | 2009 | 264 | 0.180 |
Why?
|
| Female | 11 | 2015 | 16197 | 0.170 |
Why?
|
| Aging | 2 | 2004 | 1593 | 0.160 |
Why?
|
| Treatment Outcome | 5 | 2008 | 3478 | 0.150 |
Why?
|
| H-2 Antigens | 2 | 2008 | 2 | 0.150 |
Why?
|
| Survival Analysis | 3 | 2008 | 298 | 0.150 |
Why?
|
| Transfection | 2 | 2008 | 125 | 0.150 |
Why?
|
| Genetic Heterogeneity | 1 | 2015 | 9 | 0.140 |
Why?
|
| Precision Medicine | 1 | 2015 | 24 | 0.140 |
Why?
|
| Interferon-gamma | 2 | 2008 | 109 | 0.140 |
Why?
|
| Molecular Targeted Therapy | 1 | 2015 | 31 | 0.140 |
Why?
|
| Foramen Magnum | 2 | 2005 | 5 | 0.140 |
Why?
|
| Humans | 12 | 2015 | 29337 | 0.130 |
Why?
|
| Cell Line | 2 | 2008 | 298 | 0.130 |
Why?
|
| Immune Evasion | 1 | 2015 | 4 | 0.130 |
Why?
|
| Headache | 1 | 2015 | 43 | 0.130 |
Why?
|
| Carcinogenesis | 1 | 2015 | 21 | 0.130 |
Why?
|
| Adult | 6 | 2015 | 8601 | 0.130 |
Why?
|
| Immune Tolerance | 2 | 2015 | 22 | 0.120 |
Why?
|
| Cytokines | 2 | 2012 | 347 | 0.110 |
Why?
|
| Killer Cells, Natural | 1 | 2012 | 91 | 0.100 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2009 | 145 | 0.100 |
Why?
|
| Cell Survival | 2 | 2007 | 169 | 0.090 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2009 | 31 | 0.090 |
Why?
|
| Brain | 3 | 2008 | 1689 | 0.080 |
Why?
|
| DNA, Complementary | 1 | 2008 | 28 | 0.080 |
Why?
|
| Male | 6 | 2015 | 15621 | 0.080 |
Why?
|
| Forkhead Transcription Factors | 1 | 2008 | 20 | 0.080 |
Why?
|
| CD4 Antigens | 1 | 2008 | 35 | 0.080 |
Why?
|
| Spleen | 1 | 2008 | 51 | 0.080 |
Why?
|
| Immunophenotyping | 1 | 2008 | 80 | 0.080 |
Why?
|
| Chromans | 1 | 2007 | 2 | 0.080 |
Why?
|
| Sensitivity and Specificity | 2 | 2006 | 553 | 0.080 |
Why?
|
| Cell Culture Techniques | 1 | 2007 | 44 | 0.070 |
Why?
|
| Manometry | 1 | 2006 | 18 | 0.070 |
Why?
|
| Hydrocephalus | 1 | 2006 | 25 | 0.070 |
Why?
|
| Immunotherapy, Active | 1 | 2006 | 3 | 0.070 |
Why?
|
| Drug Therapy, Combination | 1 | 2007 | 241 | 0.070 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2006 | 81 | 0.070 |
Why?
|
| Case-Control Studies | 2 | 2005 | 638 | 0.070 |
Why?
|
| Transplantation, Homologous | 2 | 2003 | 277 | 0.070 |
Why?
|
| Neoplasm Transplantation | 1 | 2005 | 23 | 0.070 |
Why?
|
| Interleukin-18 | 1 | 2005 | 11 | 0.070 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2005 | 22 | 0.070 |
Why?
|
| Blood Flow Velocity | 1 | 2005 | 19 | 0.070 |
Why?
|
| Time Factors | 3 | 2004 | 1616 | 0.070 |
Why?
|
| Age Factors | 2 | 2006 | 843 | 0.070 |
Why?
|
| Astrocytes | 1 | 2007 | 122 | 0.070 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2005 | 19 | 0.070 |
Why?
|
| Genetic Vectors | 1 | 2005 | 60 | 0.070 |
Why?
|
| Congo Red | 1 | 2004 | 2 | 0.070 |
Why?
|
| Regional Blood Flow | 1 | 2004 | 15 | 0.070 |
Why?
|
| Staining and Labeling | 1 | 2004 | 22 | 0.070 |
Why?
|
| Spinal Canal | 1 | 2004 | 15 | 0.060 |
Why?
|
| Amyloid beta-Protein Precursor | 1 | 2004 | 22 | 0.060 |
Why?
|
| Skull | 1 | 2004 | 25 | 0.060 |
Why?
|
| Brain Stem | 1 | 2004 | 25 | 0.060 |
Why?
|
| Interleukin-1 | 1 | 2004 | 78 | 0.060 |
Why?
|
| Cell Count | 1 | 2004 | 99 | 0.060 |
Why?
|
| Middle Aged | 3 | 2015 | 9823 | 0.060 |
Why?
|
| Spinal Cord | 1 | 2005 | 103 | 0.060 |
Why?
|
| Mice, Transgenic | 1 | 2004 | 248 | 0.060 |
Why?
|
| Analysis of Variance | 1 | 2004 | 321 | 0.060 |
Why?
|
| Melanoma, Experimental | 1 | 2003 | 5 | 0.060 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2003 | 4 | 0.060 |
Why?
|
| Injections, Intralesional | 1 | 2003 | 28 | 0.060 |
Why?
|
| Immunohistochemistry | 1 | 2004 | 391 | 0.060 |
Why?
|
| RNA, Neoplasm | 1 | 2003 | 17 | 0.060 |
Why?
|
| Meningioma | 1 | 2003 | 18 | 0.060 |
Why?
|
| Genetic Therapy | 1 | 2003 | 89 | 0.060 |
Why?
|
| Nerve Tissue Proteins | 1 | 2003 | 173 | 0.050 |
Why?
|
| Gene Expression Profiling | 1 | 2003 | 153 | 0.050 |
Why?
|
| Membrane Proteins | 1 | 2003 | 173 | 0.050 |
Why?
|
| Hippocampus | 1 | 2003 | 274 | 0.050 |
Why?
|
| Adolescent | 1 | 2005 | 2279 | 0.040 |
Why?
|
| Signal Transduction | 2 | 2015 | 482 | 0.040 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2009 | 58 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2015 | 14 | 0.030 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2015 | 19 | 0.030 |
Why?
|
| Hydrodynamics | 1 | 2015 | 1 | 0.030 |
Why?
|
| Valsalva Maneuver | 1 | 2015 | 4 | 0.030 |
Why?
|
| Tumor Escape | 1 | 2015 | 1 | 0.030 |
Why?
|
| Phytochemicals | 1 | 2015 | 3 | 0.030 |
Why?
|
| Antigen Presentation | 1 | 2015 | 21 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2015 | 75 | 0.030 |
Why?
|
| Aged | 1 | 2005 | 9448 | 0.030 |
Why?
|
| CD3 Complex | 1 | 2009 | 13 | 0.020 |
Why?
|
| Coculture Techniques | 1 | 2009 | 37 | 0.020 |
Why?
|
| Culture Media, Conditioned | 1 | 2009 | 37 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2009 | 130 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2009 | 209 | 0.020 |
Why?
|
| Gene Expression | 1 | 2009 | 226 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2009 | 323 | 0.020 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2007 | 11 | 0.020 |
Why?
|
| Lactic Acid | 1 | 2007 | 16 | 0.020 |
Why?
|
| Cell Death | 1 | 2007 | 61 | 0.020 |
Why?
|
| Glucose | 1 | 2007 | 59 | 0.020 |
Why?
|
| Energy Metabolism | 1 | 2007 | 52 | 0.020 |
Why?
|
| Transduction, Genetic | 1 | 2006 | 18 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2007 | 437 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2006 | 227 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2006 | 135 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2009 | 724 | 0.020 |
Why?
|
| Patient Selection | 1 | 2006 | 232 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2006 | 788 | 0.020 |
Why?
|
| Synaptosomal-Associated Protein 25 | 1 | 2003 | 3 | 0.010 |
Why?
|
| Prognosis | 1 | 2006 | 840 | 0.010 |
Why?
|
| Immunity | 1 | 2003 | 24 | 0.010 |
Why?
|
| Adenocarcinoma | 1 | 2003 | 189 | 0.010 |
Why?
|
| Phenotype | 1 | 2003 | 355 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2003 | 284 | 0.010 |
Why?
|
| Algorithms | 1 | 2003 | 400 | 0.010 |
Why?
|